West Pharmaceutical Services Inc (WST)
Official siteHEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NYSE
Market Cap: $29.01B
Last updated: Nov 17, 2026 at 11:06 AM ET
West Pharmaceutical Services Inc (WST) Financials: Revenue, Profit and Cash Flow
West Pharmaceutical Services reported revenue of $3.07B for the fiscal year ended Dec 31, 2025, up 6.3% from the year before. That year, net income was $493.70M with a net margin of 16.1%, operating cash flow was $754.80M and free cash flow was $468.90M. The quarter ended Jun 30, 2026 had revenue of $872.30M and net income of $154.00M.
Revenue and Margins
The operating margin was 19.0% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $1.51B, a compound annual rate of 8.2%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $3.07B | +6.3% | 35.9% | 19.0% | 16.1% |
| Dec 2024 | $2.89B | -1.9% | 34.5% | 19.7% | 17.0% |
| Dec 2023 | $2.95B | +2.2% | 38.3% | 22.9% | 20.1% |
| Dec 2022 | $2.89B | +2.0% | 39.4% | 25.4% | 20.3% |
| Dec 2021 | $2.83B | +31.9% | 41.5% | 26.6% | 23.4% |
| Dec 2020 | $2.15B | +16.7% | 35.8% | 19.0% | 16.1% |
| Dec 2019 | $1.84B | +7.1% | 32.9% | 16.1% | 13.1% |
| Dec 2018 | $1.72B | +7.4% | 31.8% | 14.0% | 12.0% |
| Dec 2017 | $1.60B | +6.0% | 32.1% | 14.1% | 9.4% |
| Dec 2016 | $1.51B | N/A | 33.2% | 12.9% | 9.5% |
Income Statement
In the fiscal year ended Dec 2025, net income rose 0.2% from the year before. In the quarter ended Jun 2026, net income rose 16.8% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.07B | $2.89B | $2.95B | $2.89B | $2.83B | $2.15B | $1.84B | $1.72B | $1.60B | $1.51B |
| Cost of revenue | $1.97B | $1.89B | $1.82B | $1.75B | $1.66B | $1.38B | $1.23B | $1.17B | $1.09B | $1.01B |
| Gross profit | $1.10B | $998.50M | $1.13B | $1.14B | $1.18B | $767.80M | $605.70M | $545.40M | $512.90M | $501.40M |
| Research and development | $74.30M | $69.10M | $68.40M | $58.50M | $52.80M | $46.90M | $38.90M | $40.30M | $39.10M | $36.80M |
| Operating income | $584.90M | $569.90M | $676.00M | $734.00M | $752.30M | $406.90M | $296.60M | $240.30M | $225.80M | $195.20M |
| Net income | $493.70M | $492.70M | $593.40M | $585.90M | $661.80M | $346.20M | $241.70M | $206.90M | $150.70M | $143.60M |
| EBITDA | $755.30M | $724.30M | $816.30M | $803.30M | $878.40M | $517.20M | $399.90M | $351.40M | $325.60M | $287.50M |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $872.30M | $844.90M | $805.00M | $804.60M | $766.50M | $698.00M | $748.80M | $746.90M | $702.10M | $695.40M | $732.00M | $747.40M |
| Gross profit | $329.20M | $296.40M | $303.90M | $294.30M | $273.90M | $231.90M | $273.60M | $264.70M | $230.00M | $230.20M | $278.20M | $288.30M |
| Operating income | $179.10M | $177.10M | $156.60M | $167.60M | $153.70M | $107.00M | $159.60M | $161.30M | $126.20M | $122.80M | $160.90M | $177.30M |
| Net income | $154.00M | $138.80M | $132.10M | $140.00M | $131.80M | $89.80M | $130.10M | $136.00M | $111.30M | $115.30M | $137.00M | $161.30M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded total debt of $225.50M by $565.80M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $4.27B | $3.64B | $3.83B | $3.62B | $3.31B | $2.79B | $2.34B | $1.98B | $1.86B | $1.72B |
| Current assets | $1.98B | $1.54B | $1.94B | $1.92B | $1.74B | $1.37B | $1.06B | $894.40M | $743.50M | $641.90M |
| Cash and equivalents | $791.30M | $484.60M | $853.90M | $894.30M | $762.60M | $615.50M | $439.10M | $337.40M | $235.90M | $203.00M |
| Total liabilities | $1.09B | $961.10M | $948.50M | $931.90M | $978.40M | $939.30M | $768.20M | $582.60M | $582.90M | $599.20M |
| Short-term debt | $22.70M | $18.80M | $134.00M | $2.20M | $44.20M | $2.30M | $2.30M | $100.00K | $0 | $2.40M |
| Long-term debt | $202.80M | $202.60M | $72.80M | $206.70M | $208.80M | $252.90M | $255.00M | $196.00M | $197.00M | $226.20M |
| Shareholder equity | $3.18B | $2.68B | $2.88B | $2.68B | $2.34B | $1.85B | $1.57B | $1.40B | $1.28B | $1.12B |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $4.08B | $4.11B | $4.27B | $4.11B | $3.95B | $3.62B | $3.64B | $3.68B | $3.49B | $3.60B | $3.83B | $3.75B |
| Total liabilities | $1.09B | $1.12B | $1.09B | $1.05B | $1.02B | $935.10M | $961.10M | $923.00M | $912.60M | $921.70M | $948.50M | $886.50M |
| Cash and equivalents | $435.80M | $521.40M | $791.30M | $628.50M | $509.70M | $404.20M | $484.60M | $490.90M | $446.20M | $601.80M | $853.90M | $898.60M |
| Shareholder equity | $2.99B | $2.99B | $3.18B | $3.05B | $2.93B | $2.68B | $2.68B | $2.75B | $2.58B | $2.68B | $2.88B | $2.87B |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 62.1% of operating cash flow. Dividends and share repurchases together came to 41.6% of it.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $754.80M | $653.40M | $776.50M | $724.00M | $584.00M | $472.50M | $367.20M | $288.60M | $263.30M | $219.40M |
| Capital expenditures | $285.90M | $377.00M | $362.00M | $284.60M | $253.40M | $174.40M | $126.40M | $104.70M | $130.80M | $170.20M |
| Free cash flow | $468.90M | $276.40M | $414.50M | $439.40M | $330.60M | $298.10M | $240.80M | $183.90M | $132.50M | $49.20M |
| Dividends paid | $61.20M | $59.10M | $57.00M | $54.10M | $51.10M | $48.10M | $45.10M | $42.10M | $39.10M | $35.80M |
| Share repurchases | $134.00M | $560.90M | $438.30M | $202.80M | $137.10M | $115.50M | $83.10M | $70.80M | $74.40M | $52.20M |
| Investing cash flow | -$285.90M | -$378.70M | -$368.70M | -$288.20M | -$253.10M | -$179.50M | -$228.00M | -$100.80M | -$133.60M | -$175.80M |
| Financing cash flow | -$185.10M | -$622.60M | -$459.60M | -$293.60M | -$168.10M | -$137.10M | -$36.80M | -$80.70M | -$109.00M | -$113.90M |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $124.00M | $89.90M | $251.10M | $197.20M | $177.10M | $129.40M | $190.10M | $180.10M | $165.00M | $118.20M | $239.10M | $230.10M |
| Capital expenditures | $43.20M | $42.70M | $76.10M | $63.30M | $75.20M | $71.30M | $104.90M | $81.30M | $100.20M | $90.60M | $108.70M | $95.80M |
| Free cash flow | $80.80M | $47.20M | $175.00M | $133.90M | $101.90M | $58.10M | $85.20M | $98.80M | $64.80M | $27.60M | $130.40M | $134.30M |
Frequently Asked Questions About WST
What is West Pharmaceutical Services' annual revenue?
West Pharmaceutical Services reported revenue of $3.07B for the fiscal year ended Dec 31, 2025.
How fast is West Pharmaceutical Services' revenue growing?
Revenue was up 6.3% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 2.1%.
Is West Pharmaceutical Services profitable?
Yes. West Pharmaceutical Services reported net income of $493.70M for the fiscal year ended Dec 31, 2025, with a net margin of 16.1%.
How much free cash flow does WST generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $754.80M minus capital expenditures of $285.90M produced free cash flow of $468.90M.
How much debt does West Pharmaceutical Services have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $202.80M, short-term debt of $22.70M and cash and equivalents of $791.30M.
WST pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors